Multicenter, cross-sectional study of the costs of illness and cost-driving factors in adult patients with epilepsy.
HEOR
antiseizure medication
burden of illness
cost containment
seizures
Journal
Epilepsia
ISSN: 1528-1167
Titre abrégé: Epilepsia
Pays: United States
ID NLM: 2983306R
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
revised:
02
01
2022
received:
08
12
2021
accepted:
12
01
2022
pubmed:
23
2
2022
medline:
14
4
2022
entrez:
22
2
2022
Statut:
ppublish
Résumé
This study was undertaken to quantify epilepsy-related costs of illness (COI) in Germany and identify cost-driving factors. COI were calculated among adults with epilepsy of different etiologies and severities. Multiple regression analysis was applied to determine any epilepsy-related and sociodemographic factors that serve as cost-driving factors. In total, 486 patients were included, with a mean age of 40.5 ± 15.5 years (range = 18-83 years, 58.2% women). Mean 3-month COI were estimated at €4911, €2782, and €2598 for focal, genetic generalized, and unclassified epilepsy, respectively. The mean COI for patients with drug-refractory epilepsy (DRE; €7850) were higher than those for patients with non-DRE (€4720), patients with occasional seizures (€3596), or patients with seizures in remission for >1 year (€2409). Identified cost-driving factors for total COI included relevant disability (unstandardized regression coefficient b = €2218), poorer education (b = €2114), living alone (b = €2612), DRE (b = €1831), and frequent seizures (b = €2385). Younger age groups of 18-24 years (b = -€2945) and 25-34 years (b = -€1418) were found to have lower overall expenditures. A relevant disability (b = €441), DRE (b = €1253), frequent seizures (b = €735), and the need for specialized daycare (b = €749) were associated with higher direct COI, and poorer education (b = €1969), living alone (b = €2612), the presence of a relevant disability (b = €1809), DRE (b = €1831), and frequent seizures (b = €2385) were associated with higher indirect COI. This analysis provides up-to-date COI data for use in further health economics analyses, highlighting the high economic impacts associated with disease severity, disability, and disease-related loss of productivity among adult patients with epilepsy. The identified cost drivers could be used as therapeutic and socioeconomic targets for future cost-containment strategies.
Banques de données
DRKS
['DRKS00022024']
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
904-918Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.
Références
Finkelstein E, Corso P. Cost-of-illness analyses for policy making: a cautionary tale of use and misuse. Expert Rev Pharmacoecon Outcomes Res. 2003;3:367-9.
Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20:327-37.
O'Donnell JC. Personalized medicine and the role of health economics and outcomes research: issues, applications, emerging trends, and future research. Value Health. 2013;16(6):S1-3.
Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:522-30.
Fisher RS, Cross JH, D'Souza C, French JA, Haut SR, Higurashi N, et al. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia. 2017;58:531-42.
Allers K, Essue BM, Hackett ML, Muhunthan J, Anderson CS, Pickles K, et al. The economic impact of epilepsy: a systematic review. BMC Neurol. 2015;15:245.
Strzelczyk A, Griebel C, Lux W, Rosenow F, Reese JP. The burden of severely drug-refractory epilepsy: a comparative longitudinal evaluation of mortality, morbidity, resource use, and cost using German health insurance data. Front Neurol. 2017;8:712.
Strzelczyk A, Kalski M, Bast T, Wiemer-Kruel A, Bettendorf U, Kay L, et al. Burden-of-illness and cost-driving factors in Dravet syndrome patients and carers: a prospective, multicenter study from Germany. Eur J Paediatr Neurol. 2019;23:392-403.
Strzelczyk A, Reese JP, Dodel R, Hamer HM. Cost of epilepsy: a systematic review. Pharmacoeconomics. 2008;26:463-76.
Willems LM, Schubert-Bast S, Grau J, Hertzberg C, Kurlemann G, Wiemer-Kruel A, et al. Health-related quality of life in children and adolescents with tuberous sclerosis complex and their caregivers: A multicentre cohort study from Germany. Eur J Paediatr Neurol. 2021;35:111-22.
Willems LM, Hamer HM, Knake S, Rosenow F, Reese JP, Strzelczyk A. General trends in prices and prescription patterns of anticonvulsants in Germany between 2000 and 2017: analysis of national and cohort-based data. Appl Health Econ Health Policy. 2019;17:707-22.
Willems LM, Richter S, Watermann N, Bauer S, Klein KM, Reese JP, et al. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany from 2003 to 2013-a ten-year overview. Epilepsy Behav. 2018;83:28-35.
Staab TR, Walter M, Mariotti Nesurini S, Dintsios CM, Graf von der Schulenburg JM, Amelung VE, et al. "Market withdrawals" of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations. Health Econ Rev. 2018;8:23.
Kortland LM, Alfter A, Bähr O, Carl B, Dodel R, Freiman TM, et al. Costs and cost-driving factors for acute treatment of adults with status epilepticus: a multicenter cohort study from Germany. Epilepsia. 2016;57:2056-66.
Strzelczyk A, Haag A, Reese JP, Nickolay T, Oertel WH, Dodel R, et al. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany. Epilepsy Behav. 2013;27:433-8.
Schöffski O, von der Schulenburg JM. Gesundheitsökonomische Evaluationen. 4th edition. Berlin, Germany: Springer; 2012.
Graf von der Schulenburg JM, Greiner W, Jost F, Klusen N, Kubin M, Leidl R, et al. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. Value Health. 2008;11(4):539-44.
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Technical document on cost estimation. https://www.iqwig.de/en/about-us/methods/. Accessed October 09, 2008.
Schwabe U. Antiepileptika. In: Schwabe U, Ludwig W-D, editors. Arzneiverordnungs-Report 2020. Berlin, Heidelberg, Germany: Springer-Verlag; 2020:365-78.
Krauth C, Hessel F, Hansmeier T, Wasem J, Seitz R, Schweikert B. Empirical standard costs for health economic evaluation in Germany-a proposal by the working group Methods in Health Economic Evaluation. Gesundheitswesen. 2005;67:736-46.
Strzelczyk A, Bergmann A, Biermann V, Braune S, Dieterle L, Forth B, et al. Neurologist adherence to clinical practice guidelines and costs in patients with newly diagnosed and chronic epilepsy in Germany. Epilepsy Behav. 2016;64:75-82.
Strzelczyk A, Nickolay T, Bauer S, Haag A, Knake S, Oertel WH, et al. Evaluation of health-care utilization among adult patients with epilepsy in Germany. Epilepsy Behav. 2012;23:451-7.
Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:512-21.
Levira F, Thurman DJ, Sander JW, Hauser WA, Hesdorffer DC, Masanja H, et al. Premature mortality of epilepsy in low- and middle-income countries: a systematic review from the Mortality Task Force of the International League Against Epilepsy. Epilepsia. 2017;58:6-16.
von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806-8.
Beghi E, Garattini L, Ricci E, Cornago D, Parazzini F, EPICOS Group. Direct cost of medical management of epilepsy among adults in Italy: a prospective cost-of-illness study (EPICOS). Epilepsia. 2004;45:171-8.
Strzelczyk A, Reese JP, Oertel WH, Dodel R, Rosenow F, Hamer HM. Costs of epilepsy and their predictors: cross-sectional study in Germany and review of literature. Epileptology. 2013;1:55-60.
Tetto A, Manzoni P, Millul A, Beghi E, Garattini L, Tartara A, et al. The costs of epilepsy in Italy: a prospective cost-of-illness study in referral patients with disease of different severity. Epilepsy Res. 2002;48:207-16.
Desgagne A, Castilloux AM, Angers JF, LeLorier J. The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data. Pharmacoeconomics. 1998;13:487-97.
Pirker S, Graef A, Gachter M, Baumgartner C. Costs of epilepsy in Austria: unemployment as a primary driving factor. Seizure. 2021;89:24-9.
Begley CE, Durgin TL. The direct cost of epilepsy in the United States: a systematic review of estimates. Epilepsia. 2015;56:1376-87.
Cramer JA, Wang ZJ, Chang E, Powers A, Copher R, Cherepanov D, et al. Healthcare utilization and costs in adults with stable and uncontrolled epilepsy. Epilepsy Behav. 2014;31:356-62.
Peña P, Sancho J, Rufo M, Martínez S, Rejas J, LINCE Study Collaborative Group. Driving cost factors in adult outpatients with refractory epilepsy: a daily clinical practice in clinics of neurology in Spain. Epilepsy Res. 2009;83:133-43.
Mengel D, Fraune L, Sommer N, Stettner M, Reese JP, Dams J, et al. Costs of illness in chronic inflammatory demyelinating polyneuropathy in Germany. Muscle Nerve. 2018;58:681-7.
Flachenecker P, Kobelt G, Berg J, Capsa D, Gannedahl M, European Multiple Sclerosis Platform. New insights into the burden and costs of multiple sclerosis in Europe: results for Germany. Mult Scler. 2017;23:78-90.
Foster E, Chen Z, Zomer E, Rychkova M, Carney P, O'Brien TJ, et al. The costs of epilepsy in Australia: a productivity-based analysis. Neurology. 2020;95:e3221-31.
Riechmann J, Strzelczyk A, Reese JP, Boor R, Stephani U, Langner C, et al. Costs of epilepsy and cost-driving factors in children, adolescents, and their caregivers in Germany. Epilepsia. 2015;56(9):1388-97.
Grau J, Zöllner JP, Schubert-Bast S, Kurlemann G, Hertzberg C, Wiemer-Kruel A, et al. Direct and indirect costs and cost-driving factors of tuberous sclerosis complex in children, adolescents, and caregivers: a multicenter cohort study. Orphanet J Rare Dis. 2021;16:282.
Zöllner JP, Grau J, Rosenow F, Sauter M, Knuf M, Kurlemann G, et al. Direct and indirect costs and cost-driving factors in adults with tuberous sclerosis complex: a multicenter cohort study and a review of the literature. Orphanet J Rare Dis. 2021;16:250.
Quintana M, Fonseca E, Sanchez-Lopez J, Mazuela G, Santamarina E, Abraira L, et al. The economic burden of newly diagnosed epilepsy in Spain. Epilepsy Behav. 2021;125:108395.
Taylor RS, Sander JW, Taylor RJ, Baker GA. Predictors of health-related quality of life and costs in adults with epilepsy: a systematic review. Epilepsia. 2011;52:2168-80.
Willems LM, Kondziela JM, Knake S, Schulz J, Neif B, Schade B, et al. Counseling and social work for people with epilepsy in Germany: a cross-sectional multicenter study on demand, frequent content, patient satisfaction, and burden-of-disease. Epilepsy Behav. 2019;92:114-20.
Leenen LAM, Wijnen BFM, Kessels AGH, Chan H, de Kinderen RJA, Evers S, et al. Effectiveness of a multicomponent self-management intervention for adults with epilepsy (ZMILE study): a randomized controlled trial. Epilepsy Behav. 2018;80:259-65.
May TW, Pfäfflin M. The efficacy of an educational treatment program for patients with epilepsy (MOSES): results of a controlled, randomized study. Modular Service Package Epilepsy. Epilepsia. 2002;43:539-49.
Willems LM, Balcik Y, Noda AH, Siebenbrodt K, Leimeister S, McCoy J, et al. SARS-CoV-2-related rapid reorganization of an epilepsy outpatient clinic from personal appointments to telemedicine services: a German single-center experience. Epilepsy Behav. 2020;112:107483.
Markanday S, Brennan SL, Gould H, Pasco JA. Sex-differences in reasons for non-participation at recruitment: Geelong Osteoporosis Study. BMC Res Notes. 2013;6:104.
Kondziela JM, Schulz J, Brunst B, Fuchs S, Gerlinger S, Neif B, et al. Acceptance, demand, reasons for consultation and outcome of counseling on epilepsy in Hesse and Lower Franconia. Nervenarzt. 2019;90:832-9.
Schnabel S, Neininger MP, Bernhard MK, Merkenschlager A, Kiess W, Bertsche T, et al. Epilepsy: a cross-sectional study of paediatricians and general practitioners on their experiences, knowledge and handling of the disease. Epileptic Disord. 2019;21:197-205.